Cargando…

Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review

SUMMARY. BACKGROUND. Pneumocystis jirovecii pneumonia (PCP) is an opportunistic and prevalent fungal infection in immunocompromised hosts, including patients after kidney transplantation (KTx). It is a life threatening infection. While with effective prophylaxis it became less common, it still remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnas, Dominykas, Jankauskienė, Augustina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Vilnius University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311846/
https://www.ncbi.nlm.nih.gov/pubmed/34393636
http://dx.doi.org/10.15388/Amed.2020.28.1.5
_version_ 1783729042018533376
author Varnas, Dominykas
Jankauskienė, Augustina
author_facet Varnas, Dominykas
Jankauskienė, Augustina
author_sort Varnas, Dominykas
collection PubMed
description SUMMARY. BACKGROUND. Pneumocystis jirovecii pneumonia (PCP) is an opportunistic and prevalent fungal infection in immunocompromised hosts, including patients after kidney transplantation (KTx). It is a life threatening infection. While with effective prophylaxis it became less common, it still remains an issue among solid organ transplant (SOT) recipients during the first year. There are no specific clinical signs for PCP. Computed tomography (CT) is a better method for detecting PCP, but definite diagnosis can only be made by identification of the microorganism either by a microscopy or by a polymerase chain reaction (PCR). CLINICAL CASE. We present a case of a 17 year old with severe PCP 13 months after KTx followed by reduction in kidney function and respiratory compromise. The pathogen was detected by PCR from bronchoalveolar lavage fluid (BALF) and patient was treated successfully with trimethoprim-sulfamethoxazole (TMPSMX). Patient’s condition, respiratory status and kidney function gradually improved. Our presented case is unusual because patient had no known risk factors for PCP and he was more than one year after KTx, what is considered rare. In addition patient and his parents delayed in notifying the treating physician about ongoing symptoms because did not deem them important enough. CONCLUSIONS. Clinicians treating patients in risk groups for PCP must always remain vigilant even in era of effective prophylaxis. The vigilance should also extend to the patient and patient’s family.
format Online
Article
Text
id pubmed-8311846
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Vilnius University Press
record_format MEDLINE/PubMed
spelling pubmed-83118462021-08-13 Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review Varnas, Dominykas Jankauskienė, Augustina Acta Med Litu Case Studies SUMMARY. BACKGROUND. Pneumocystis jirovecii pneumonia (PCP) is an opportunistic and prevalent fungal infection in immunocompromised hosts, including patients after kidney transplantation (KTx). It is a life threatening infection. While with effective prophylaxis it became less common, it still remains an issue among solid organ transplant (SOT) recipients during the first year. There are no specific clinical signs for PCP. Computed tomography (CT) is a better method for detecting PCP, but definite diagnosis can only be made by identification of the microorganism either by a microscopy or by a polymerase chain reaction (PCR). CLINICAL CASE. We present a case of a 17 year old with severe PCP 13 months after KTx followed by reduction in kidney function and respiratory compromise. The pathogen was detected by PCR from bronchoalveolar lavage fluid (BALF) and patient was treated successfully with trimethoprim-sulfamethoxazole (TMPSMX). Patient’s condition, respiratory status and kidney function gradually improved. Our presented case is unusual because patient had no known risk factors for PCP and he was more than one year after KTx, what is considered rare. In addition patient and his parents delayed in notifying the treating physician about ongoing symptoms because did not deem them important enough. CONCLUSIONS. Clinicians treating patients in risk groups for PCP must always remain vigilant even in era of effective prophylaxis. The vigilance should also extend to the patient and patient’s family. Vilnius University Press 2021 2021-01-25 /pmc/articles/PMC8311846/ /pubmed/34393636 http://dx.doi.org/10.15388/Amed.2020.28.1.5 Text en Copyright © 2021 Dominykas Varnas, Augustina Jankauskienė. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Studies
Varnas, Dominykas
Jankauskienė, Augustina
Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review
title Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review
title_full Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review
title_fullStr Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review
title_full_unstemmed Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review
title_short Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review
title_sort pneumocystis jirovecii pneumonia in a kidney transplant recipient 13 months after transplantation: a case report and literature review
topic Case Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311846/
https://www.ncbi.nlm.nih.gov/pubmed/34393636
http://dx.doi.org/10.15388/Amed.2020.28.1.5
work_keys_str_mv AT varnasdominykas pneumocystisjiroveciipneumoniainakidneytransplantrecipient13monthsaftertransplantationacasereportandliteraturereview
AT jankauskieneaugustina pneumocystisjiroveciipneumoniainakidneytransplantrecipient13monthsaftertransplantationacasereportandliteraturereview